TMCnet1m
Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition
Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624's novel epigenetic mechanism of action on neurological pathways. The findings provide ...
manilatimes57m
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2024 was $123.5 million (+36 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2024 was $437 million (+34 ...